Summit Therapeutics’ investigational bispecific antibody, Ivonescimab, has achieved clinically significant benefits in a Phase III trial (HARMONi-2) compared to the current standard of care, Pembrolizumab, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
HARMONi-2 evaluated Ivonescimab monotherapy against Pembrolizumab monotherapy in patients with PD-L1-positive tumors. The trial showed a statistically significant improvement in progression-free survival (PFS) with Ivonescimab across various subgroups, including patients with low or high PD-L1 expression, different histologies, and high-risk patients.
The HARMONi-2 trial results will be presented at the upcoming World Conference on Lung Cancer (WCLC 2024). Additionally, Phase II data on Ivonescimab in the perioperative setting for resectable NSCLC will also be presented.
Ivonescimab is the first to demonstrate a clinically meaningful benefit over Pembrolizumab in a randomized Phase III clinical trial in NSCLC. This breakthrough has the potential to transform the treatment landscape for patients with advanced lung cancer.
The WCLC presentations will provide detailed insights into the efficacy and safety of Ivonescimab, further solidifying its position as a promising therapeutic option for NSCLC patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.